Related Experiment Video
Updated: Sep 27, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
[Clinical efficacy of 0.2% brimonidine in patients with open-angle glaucoma or ocular hypertension]
1Department of Ophthalmology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Objective:
To evaluate the efficacy and safety of 0.2% brimonidine administered in patients with glaucoma or ocular hypertension.
Methods:
Twenty-five patients (41 eyes) with primary open-angle glaucoma or ocular hypertension were enrolled in this prospective study. Eye drops of 0.2% brimonidine were used twice daily for 6 months and the patients were examined every month after the treatment, including the trough intraocular pressure (IOP, IOP 12 h after 0.2% brimonidine was administrated) and the peak IOP (IOP 12 h after 0.2% brimonidine was administrated). The visual field was examined every three months.
Results:
The use of 0.2% brimonidine significantly lowered the trough IOP and the peak IOP (P < 0.05). Every point of the IOP diurnal curve significantly decreased compared with the baseline (P < 0.05). The visual field had no significant change 3 months or 6 months after the treatment with 0.2% brimonidine. No serious systemic side effect was observed.
Conclusion:
Brimonidine is safe and effective in lowering IOP in glaucoma or ocular hypertension and is well tolerated.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Ophthalmic Drug Delivery Systems
Direct-Acting Cholinergic Agonists: Therapeutic Uses
